English speaker; 4) comparison of original and back translation; and 5) review by a clinician. RESULTS: Cultural and linguistic challenges emerged during the process. On the cultural level, the differences in the approach to suicide and its methods based on differences in tradition and availability of means required finding suitable alternatives in the target languages. On the linguistic level, it was important to differentiate between medical and psychiatric hospitalisation after a suicide attempt and appropriate solutions across languages had to be found. The process revealed an area of ambiguity in the original rating instructions which had to be clarified in the translations. Examples of these and other challenges and their solutions will be discussed in the presentation. CONCLUSIONS: The 45 language versions, of the C-SSRS (a total of over 90 translations now exist), were established according to a rigorous methodology to ensure conceptual equivalence and cultural relevance across languages. The translations may now be used in international studies to assess suicidal ideation and behaviour and facilitate the comparison and pooling of data. The analysis of the psychometric results will be necessary to see if and how suicidal ideation and behaviour compare across countries and cultures.
QL3 ACCESS TO HEALTH-RELATED QUALITY OF LIFE (HRQL) INSTRUMENTS AND THEIR TRANSLATIONS IN THE LIGHT OF EMEA RECOMMENDATIONS
Anfray C, Emery MP Mapi Research Trust, Lyon, France INTRODUCTION: The EMEA reflection paper on HRQL specifies that the claim in the Summary of Product Characteristics (SmPC) with respect to HRQL will always be considered depending on the strength of the evidence, which should be based on 6 criteria, amongst these are the justification of the choice of the HRQL instrument(s), and the evidence of validation (including for translation). To meet these requirements, users should have access to reliable and updated information. To determine if these can be met, it is necessary to review how users access information about HRQL instruments. OBJECTIVES: 1) To investigate how developers organize the release of information about their instrument; 2) to comment on the pros and cons for each identified dissemination strategy; 3) To make recommendations for instrument developers to facilitate users' access to information. METHODS: we conducted a review of the 2,850 information requests addressed to our Information Resources Centre in 2007. The requests were categorized according to the type of information needed: 1) information about the original instrument; 2) conditions of access/use of instruments/translations; 3) validity of instruments/translations; 4) translation certification; 5) intellectual property. To address these, we made 900 contacts with developers, translators, publishers and other licensing authorities. RESULTS: Out of the dissemination strategies identified and reviewed, five trends emerged between two extremes: 1) uncontrolled, de-centralized, free access to non-updated information without developer's input; 2) controlled, copyright-protected, centralized, fee-paying access to reliable and updated information with developer's input. Advantages and disadvantages of strategies will be discussed. Examples demonstrate that the controlled strategy is more compliant with the EMEA evidence requirements. CON-CLUSION: Findings indicate that how a user can comply or not with the EMEA requirements is directly related to how developers organize the release of information about their questionnaire and translations. Promoting a controlled, centralized system with developers' input may facilitate access to reliable and updated information. C30 ) can satisfactorily predict EQ-5D, SF-6D and 15D utilities. The QLQ-C30 measures health-related quality of life (HRQOL) using a global scale, five functional scales and eight symptom scales/items and like most HRQOL instruments provides a profile of scores instead of an overall preference-based index, precluding its use in cost-utility studies. METHODS: A stratified sample (N = 48) of gastrointestinal cancer patients on chemotherapy was interviewed. The survey contained the QLQ-C30, the SF-36, two multi-attribute utility instruments (EQ-5D and 15D) and socio-demographic and disease-related questions. Validity of QLQ-C30 scales was assessed by testing a priori hypotheses that they would be moderately or strongly correlated with SF-36 scales measuring similar HRQOL dimensions and that younger subjects and those not reporting comorbid conditions would have better scores. Linear regression analyses identified the extent to which QLQ-C30 scales could predict EQ-5D, SF-6D and 15D utilities. RESULTS: Pearson's correlations between similar QLQ-C30 and SF-36 scales ranged from 0.69 to 0.89 (P < 0.001). Subjects with coronary heart disease had worse scores on all QLQ-C30 functional scales (T-test, P < 0.05 for four scales), as did older subjects as well (ANOVA, P < 0.05 for five scales). QLQ-C30 global, functional and symptom scales were significant predictors of utility scores elicited from standard instruments. Specifically, three scales were significant (P < 0.05) predictors of EQ-5D utilities, six scales (P < 0.05) of SF-6D utilities and four scales (P < 0.001) of 15D utilities and explained large portions of variance (adjusted R 2 was 0.610, 0.833 and 0.912 respectively). Robustness of results was tested and confirmed in patient subgroups with differing HRQOL. CONCLUSIONS: Preliminary evidence has been provided supporting the appropriateness mainly of the 15D and SF-6D instruments in cancer-specific cost-utility studies, although further studies involving larger and more diverse patient samples are encouraged. 
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